PL2536764T3 - Humanizowane przeciwciała anty-CD28 - Google Patents
Humanizowane przeciwciała anty-CD28Info
- Publication number
- PL2536764T3 PL2536764T3 PL11707918T PL11707918T PL2536764T3 PL 2536764 T3 PL2536764 T3 PL 2536764T3 PL 11707918 T PL11707918 T PL 11707918T PL 11707918 T PL11707918 T PL 11707918T PL 2536764 T3 PL2536764 T3 PL 2536764T3
- Authority
- PL
- Poland
- Prior art keywords
- humanized antibodies
- humanized
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10290080A EP2361935A1 (en) | 2010-02-18 | 2010-02-18 | Anti-CD28 humanized antibodies |
| EP10290389 | 2010-07-13 | ||
| EP11707918.6A EP2536764B1 (en) | 2010-02-18 | 2011-02-16 | Anti-cd28 humanized antibodies |
| PCT/IB2011/050646 WO2011101791A1 (en) | 2010-02-18 | 2011-02-16 | Anti-cd28 humanized antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2536764T3 true PL2536764T3 (pl) | 2018-12-31 |
Family
ID=44482493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11707918T PL2536764T3 (pl) | 2010-02-18 | 2011-02-16 | Humanizowane przeciwciała anty-CD28 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8785604B2 (pl) |
| EP (2) | EP3428192B1 (pl) |
| JP (1) | JP5992340B2 (pl) |
| CA (1) | CA2788544C (pl) |
| CY (1) | CY1120707T1 (pl) |
| DK (1) | DK2536764T3 (pl) |
| ES (2) | ES2896149T3 (pl) |
| HR (1) | HRP20181360T1 (pl) |
| HU (1) | HUE039677T2 (pl) |
| LT (1) | LT2536764T (pl) |
| PL (1) | PL2536764T3 (pl) |
| PT (1) | PT2536764T (pl) |
| RS (1) | RS57667B1 (pl) |
| SI (1) | SI2536764T1 (pl) |
| SM (1) | SMT201800462T1 (pl) |
| TR (1) | TR201811185T4 (pl) |
| WO (1) | WO2011101791A1 (pl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210902A1 (en) * | 2009-01-14 | 2010-07-28 | TcL Pharma | Recombinant monovalent antibodies |
| US8785604B2 (en) * | 2010-02-18 | 2014-07-22 | Effimune | Anti-CD28 humanized antibodies |
| WO2014120916A1 (en) * | 2013-02-01 | 2014-08-07 | Bristol-Myers Squibb Company | Pegylated domain antibodies monovalent for cd28 binding and methods of use |
| US9963497B2 (en) * | 2013-12-06 | 2018-05-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 |
| KR20180087428A (ko) * | 2015-12-15 | 2018-08-01 | 오제 이뮈노테라프틱스 | 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체 |
| EP3481862A4 (en) * | 2016-07-06 | 2020-08-12 | Celgene Corporation | LOW IMMUNOGENIC ANTIBODIES AND USES THEREOF |
| EP3484448B1 (en) | 2016-07-13 | 2025-04-09 | President and Fellows of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| EP3551034A1 (en) | 2016-12-07 | 2019-10-16 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3600416B1 (en) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| EP3796934A4 (en) * | 2018-05-23 | 2022-04-06 | Manysmart Therapeutics, Inc. | BISPECIFIC T-LYMPHOCYTE ACTIVATOR AND USES THEREOF |
| MA52889A (fr) | 2018-06-15 | 2021-04-21 | Flagship Pioneering Innovations V Inc | Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| WO2020106757A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| US20250101126A1 (en) | 2021-08-05 | 2025-03-27 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| AU2022339819A1 (en) | 2021-09-03 | 2024-04-11 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| CA3234825A1 (en) | 2021-10-28 | 2023-05-04 | Lyell Immunopharma, Inc. | Methods of generating cells |
| EP4448581A2 (en) * | 2021-12-13 | 2024-10-23 | Biolegend, Inc. | Cd28 binding antibodies and antigen binding fragments thereof |
| CA3252619A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-CD28 and anti-PSMA antibodies |
| US12600801B2 (en) | 2022-07-11 | 2026-04-14 | Fred Hutchinson Cancer Center | Single-domain antibodies that bind ROR1 |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| AU2023356326A1 (en) | 2022-10-06 | 2025-03-27 | Bicara Therapeutics Inc. | Multispecific proteins and related methods |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| EP4688856A1 (en) | 2023-04-03 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Methods of improving transplant survival using il-2 receptor gamma chain antibodies |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2026006604A1 (en) | 2024-06-26 | 2026-01-02 | Lyell Immunopharma, Inc. | Feeder cell replacement |
| CN119735680B (zh) * | 2024-12-12 | 2025-07-29 | 北京同立海源生物科技有限公司 | 一种抗cd28的单克隆抗体及细胞 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6776990B2 (en) | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
| CN1272345C (zh) * | 2000-12-14 | 2006-08-30 | 安斯泰来制药有限公司 | 沉默型抗cd－28抗体及其应用 |
| ES2353273T3 (es) | 2000-12-26 | 2011-02-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticuerpos anti-cd28. |
| US6900292B2 (en) * | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
| TW200732350A (en) * | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
| EP2700651B1 (en) * | 2008-07-18 | 2019-04-10 | Bristol-Myers Squibb Company | Compositions monovalent for CD28 binding and methods of use |
| CN102257001A (zh) * | 2008-12-19 | 2011-11-23 | 诺瓦提斯公司 | 治疗自体免疫和炎性病症的可溶性多肽 |
| EP2210902A1 (en) * | 2009-01-14 | 2010-07-28 | TcL Pharma | Recombinant monovalent antibodies |
| US8785604B2 (en) * | 2010-02-18 | 2014-07-22 | Effimune | Anti-CD28 humanized antibodies |
| KR20180087428A (ko) * | 2015-12-15 | 2018-08-01 | 오제 이뮈노테라프틱스 | 인간에게 투여하기 위해 제제화된 항-cd28 인간화 항체 |
-
2011
- 2011-02-16 US US13/577,103 patent/US8785604B2/en active Active
- 2011-02-16 HU HUE11707918A patent/HUE039677T2/hu unknown
- 2011-02-16 PT PT117079186T patent/PT2536764T/pt unknown
- 2011-02-16 RS RS20180994A patent/RS57667B1/sr unknown
- 2011-02-16 LT LTEP11707918.6T patent/LT2536764T/lt unknown
- 2011-02-16 TR TR2018/11185T patent/TR201811185T4/tr unknown
- 2011-02-16 JP JP2012553431A patent/JP5992340B2/ja active Active
- 2011-02-16 DK DK11707918.6T patent/DK2536764T3/en active
- 2011-02-16 SM SM20180462T patent/SMT201800462T1/it unknown
- 2011-02-16 ES ES18177022T patent/ES2896149T3/es active Active
- 2011-02-16 CA CA2788544A patent/CA2788544C/en active Active
- 2011-02-16 EP EP18177022.3A patent/EP3428192B1/en active Active
- 2011-02-16 WO PCT/IB2011/050646 patent/WO2011101791A1/en not_active Ceased
- 2011-02-16 SI SI201131521T patent/SI2536764T1/sl unknown
- 2011-02-16 HR HRP20181360TT patent/HRP20181360T1/hr unknown
- 2011-02-16 ES ES11707918.6T patent/ES2680570T3/es active Active
- 2011-02-16 EP EP11707918.6A patent/EP2536764B1/en active Active
- 2011-02-16 PL PL11707918T patent/PL2536764T3/pl unknown
-
2014
- 2014-07-08 US US14/326,119 patent/US9562098B2/en active Active
-
2016
- 2016-12-21 US US15/386,998 patent/US10364287B2/en active Active
-
2018
- 2018-09-28 CY CY181101006T patent/CY1120707T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE039677T2 (hu) | 2019-01-28 |
| ES2896149T3 (es) | 2022-02-24 |
| CA2788544A1 (en) | 2011-08-25 |
| EP3428192B1 (en) | 2021-08-11 |
| TR201811185T4 (tr) | 2018-08-27 |
| SI2536764T1 (sl) | 2018-11-30 |
| SMT201800462T1 (it) | 2018-11-09 |
| RS57667B1 (sr) | 2018-11-30 |
| DK2536764T3 (en) | 2018-09-17 |
| US10364287B2 (en) | 2019-07-30 |
| CY1120707T1 (el) | 2019-12-11 |
| US20150071916A1 (en) | 2015-03-12 |
| PT2536764T (pt) | 2018-08-10 |
| EP2536764B1 (en) | 2018-07-04 |
| HRP20181360T1 (hr) | 2018-11-02 |
| US20170114136A1 (en) | 2017-04-27 |
| ES2680570T3 (es) | 2018-09-10 |
| EP3428192A1 (en) | 2019-01-16 |
| WO2011101791A1 (en) | 2011-08-25 |
| EP2536764A1 (en) | 2012-12-26 |
| CA2788544C (en) | 2019-03-05 |
| JP2013519389A (ja) | 2013-05-30 |
| LT2536764T (lt) | 2018-10-25 |
| JP5992340B2 (ja) | 2016-09-14 |
| US20130078236A1 (en) | 2013-03-28 |
| US9562098B2 (en) | 2017-02-07 |
| US8785604B2 (en) | 2014-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE039677T2 (hu) | Humanizált anti-CD28-ellenanyagok | |
| IL220404A (en) | Antiseptic antibodies | |
| AP4082A (en) | Anti-cd40 antibodies | |
| ES3065861T3 (en) | Interleukin-31 monoclonal antibody | |
| IL222222A0 (en) | Antibodies against csf-1r | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| IL217919A0 (en) | Humanized anti-cdcp1 antibodies | |
| ZA201302459B (en) | Antibodies | |
| GB201020738D0 (en) | Antibodies | |
| PL2603528T3 (pl) | Przeciwciała Fab-glikozylowane | |
| GB201002238D0 (en) | Antibodies | |
| IL232017A0 (en) | Antibodies of human origin to inkt | |
| ZA201208136B (en) | Humanized il-25 antibodies | |
| GB201020751D0 (en) | Antibodies | |
| GB201005062D0 (en) | Antibodies |